Koki Mori
YOU?
Author Swipe
View article: Impact of Promotional Activities on Orexin Receptor Antagonists Prescription Rates and Usage of Sleep and Antipsychotic Medications: An Interrupted Time-series Analysis Study
Impact of Promotional Activities on Orexin Receptor Antagonists Prescription Rates and Usage of Sleep and Antipsychotic Medications: An Interrupted Time-series Analysis Study Open
Lemborexant, an orexin receptor antagonist (ORA), was introduced as a safer sleep medication at our hospital, but its prescription rate remained low. To address this issue, promotion of ORAs began in August 2022. This study aimed to evalua…
View article: Short-Term Efficacy and Safety of Suvorexant and Lemborexant: A Retrospective Study
Short-Term Efficacy and Safety of Suvorexant and Lemborexant: A Retrospective Study Open
Lemborexant exerted a potent inhibitory effect on orexin 2 receptors, which could explain the longer sleep duration experienced by patients taking this drug on the first day of treatment.
View article: Analysis of drug-induced hand–foot syndrome using a spontaneous reporting system database
Analysis of drug-induced hand–foot syndrome using a spontaneous reporting system database Open
Purpose: The aim of our study was to assess the clinical features of hand–foot syndrome (HFS) associated with certain systemic chemotherapeutic drugs in a real-world setting using the Japanese Adverse Drug Event Report (JADER) database. Me…
View article: Supplementary Material for: Factors Affecting Nivolumab Therapy Outcome in Patients with Head and Neck Cancer: A Single-Center Analysis
Supplementary Material for: Factors Affecting Nivolumab Therapy Outcome in Patients with Head and Neck Cancer: A Single-Center Analysis Open
Background Nivolumab, a programmed death-1 antibody, is an immune checkpoint inhibitor approved in Japan in March 2017 for the treatment of recurrent or metastatic head and neck cancers (RM-HNCs) after platinum drug administration. This st…
View article: Experience in Using Jumihaidokuto and Orengedokuto for Skin Disorders Caused by Molecular Target Drugs
Experience in Using Jumihaidokuto and Orengedokuto for Skin Disorders Caused by Molecular Target Drugs Open
分子標的治療薬の副作用は，殺細胞性抗がん薬とは異なりざ瘡様皮疹や斑状丘疹状皮疹などの皮膚障害が高頻度に発現し，臨床的に問題となる場合がある。今回，尋常性ざ瘡への有効性が報告されている十味敗毒湯と黄連解毒湯を，分子標的治療薬による皮膚障害に対して投与し，その投与状況や効果について検討した。2013年6月から2017年6月に，分子標的治療薬の皮膚障害に対してJHT+OGTが投与された患者を対象とした。評価項目はJHT+OGT服用前後の皮疹のgrade（CTCAE v4.0）とし…
View article: Three New 5,6-Dihydro-α-pyrones Isolated from Cryptocarya nitens
Three New 5,6-Dihydro-α-pyrones Isolated from Cryptocarya nitens Open
Three new 5,6-dihydro-α-pyrone derivatives, named cryptonitenones A-C (1-3), were isolated from the leaves of Cryptocarya nitens Koord.& Valeton.Their absolute structures were determined by means of the NMR and CD spectroscopic analyses.In…
View article: Bib2vec: An Embedding-based Search System for Bibliographic Information
Bib2vec: An Embedding-based Search System for Bibliographic Information Open
We propose a novel embedding model that represents relationships among several elements in bibliographic information with high representation ability and flexibility. Based on this model, we present a novel search system that shows the rel…
View article: Bib2vec: Embedding-based Search System for Bibliographic Information
Bib2vec: Embedding-based Search System for Bibliographic Information Open
We propose a novel embedding model that represents relationships among several elements in bibliographic information with high representation ability and flexibility. Based on this model, we present a novel search system that shows the rel…